All In Biotech

Drug Trial Radar · NCT04362072

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)

Last checked: Nov 20, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

71

Actual

Start

Sep 29, 2020

Primary completion

May 29, 2024

Study completion Oct 23, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn whether the study medicine (called lorlatinib) is safe and effective for the treatment of non-small cell lung cancer that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene. This study is seeking participants whose lung cancer has progressed after receiving either alectinib or ceritinib as their first treatment. Participants will take part in this study for up to approximately 4 years, depending on when the study is completed and how their cancer responds to the study treatment. They will take lorlatinib orally (by mouth) once daily. Participants will visit the study site about every six weeks to meet with the study team. During these visits, the study team will monitor the safety and effects of lorlatinib.

Conditions

  • Carcinoma
  • Non-Small-Cell Lung

Interventions

  • LorlatinibDrug

    25 milligram (mg) tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Confirmed Overall Objective Response (OR) as Per Independent Central Review (ICR) as Assessed by RECIST v1.1Time frame: From date of first dose until documented PD or start of new anti-cancer therapy, whichever occurred earlier (maximum treatment exposure up to 42.78 months)

Locations

31 sites in 7 countries. Site status is shown where the registry gives one.

  • UCI Medical Center/Chao Family Comprehensive Cancer Center

    Orange, California

  • Rajiv Gandhi Cancer Institute And Research Centre

    New Delhi, DEL, India

  • Healthcare Global Enterprises

    Bengaluru, Karnataka, India

  • Bhakti Vedanta Hospital and Research Institute

    Thane, Maharashtra, India

  • Rajiv Gandhi Cancer Institute And Research Centre

    New Delhi, National Capital Territory of Delhi, India

  • Azienda Ospedaliera San Giuseppe Moscati

    Avellino, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, Italy

  • IRCCS Ospedale San Raffaele

    Milan, MI, Italy

  • Centro Riferimento Oncologico di Aviano - IRCCS SOC Oncologia Medica e dei Tumori Immunocorrelati

    Aviano, PN, Italy

  • Azienda Ospedaliero Universitaria di Parma

    Parma, PR, Italy

  • Azienda Ospedaliera San Camillo Forlanini

    Roma, ROME, Italy

  • AOU San Luigi Gonzaga

    Orbassano (TO), TO, Italy

  • AO Santa Maria della Misericordia

    Perugia, Umbria, Italy

  • Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna

    Lublin, Poland

  • Centrum Medyczne EVOMED

    Szczecin, Poland

  • Dom Lekarski Centrum Medyczne Outlet Park

    Szczecin, Poland

  • Pracownia Medycyny Nuklearnej, 109 Szpital Wojskowy z Przychodnia SP ZOZ

    Szczecin, Poland

  • Dom Lekarski S.A.

    Szczecin, Poland

  • Hospital Teresa Herrera (C.H.U.A.C)

    A Coruña, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • ICO L'Hospitalet (Hospital Duran i Reynals)

    L'Hospitalet de Llobregat, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, Spain

  • Kantonsspital Graubuenden

    Chur, Kanton Graubünden, Switzerland

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • NIHR/Wellcome Trust Clinical Research Facility

    Manchester, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.